Enlivex Announces Authorization from the Danish Regulatory Agency for the Company’s Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis

April 16, 2024

https://www.globenewswire.com/news-release/2024/04/16/2863512/0/en/Enlivex-Announces-Authorization-from-the-Danish-Regulatory-Agency-for-the-Company-s-Randomized-Controlled-Phase-I-II-Trial-Evaluating-Allocetra-in-Patients-with-Knee-Osteoarthritis.html

Nes-Ziona, Israel, April 16, 2024 (GLOBE NEWSWIRE) — Enlivex Therapeutics Ltd. (Nasdaq:ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the Danish Medicines Agency (DKMA) authorized the expansion into Denmark of the Company’s multi-country, randomized, controlled Phase I/II trial evaluating AllocetraTM in up to 160 patients with moderate to severe knee osteoarthritis. As previously announced, the Company received its first regulatory approval for this trial from the Israeli Ministry of Health (IMOH) in January.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.